In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Mitral annular plane systolic excursion on cardiac magnetic resonance imaging as a predictor of atrial fibrillation in hypertrophic cardiomyopathy

Session Poster session 3

Speaker Giulia Pontecorboli

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Myocardium
  • Session type : Poster Session
  • FP Number : P620

Authors : G Pontecorboli (Florence,IT), D Lazzeroni (Milan,IT), N Fierro (Milan,IT), AG Dastidar (Bristol,GB), G Biglino (Bristol,GB), EG Milano (Bristol,GB), E De Garate (Bristol,GB), P Sighal (Bristol,GB), L Moderato (Milan,IT), PG Camici (Milan,IT), C Bucciarelli-Ducci (Bristol,GB)

G Pontecorboli1 , D Lazzeroni2 , N Fierro2 , AG Dastidar3 , G Biglino3 , EG Milano3 , E De Garate3 , P Sighal3 , L Moderato2 , PG Camici2 , C Bucciarelli-Ducci3 , 1Careggi University Hospital (AOUC), Cardiovascular and Thoracic Department - Florence - Italy , 2University Vita-Salute San Raffaele - Milan - Italy , 3Bristol Heart Institute, Cardiac MRI Unit - Bristol - United Kingdom of Great Britain & Northern Ireland ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii502

Background: Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM) and is associated with major adverse cardiovascular events. The aim of our study was to identify predictors of AF in HCM patients using CMR.

Methods: Two populations with a diagnosis of HCM undergoing CMR were identified for retrospective validation (Derivation cohort n=109) and an additional prospective evaluation (Validation cohort n=109). CMR predictors of AF were evaluated with logistic regression analysis. Receiver operating characteristic (ROC) curves were used to determine the diagnostic accuracy of the identified CMR predictors of AF, and cut-off values with optimal sensitivity and specificity were calculated. A goodness-of-fit was applied in the Derivation cohort to evaluate how well the models were calibrated.

Results:Median age was 60±13 years, 51% of the patients were male. 15% of the population had a documented episode of AF (n=33).  Risk of AF was associated with higher left atrial volume index (LAVi) (OR=1.09, CI=1.05-1.14; p<0.001) and a reduced mitral annular plane systolic excursion(MAPSE) (OR=0.41, CI=0.27-0.63; p<0.001, Figure A). Moreover, the amount of LGE in the myocardial basal segments was correlated with AF risk (OR=1.018, CI=1.004-1.033; p=0.014). The area under the ROC curve for LAVi (cut-off 50 ml/m2) was 0.776 (p<0.001; sensitivity=88% and specificity=67%) while for MAPSE (cut-off 10 mm) was 0.809 (p<0.001; sensitivity=88 % and specificity=74%). The area under the ROC curve for the LAVi/MAPSE ratio (cut-off=5.0) was 0.820 (p<0.001; sensitivity=93% and specificity=71%, Figure B). These results were confirmed in the Validation cohort with a goodness-of-fit test that showed a good calibration in AF prediction between cohorts.

Conclusion: CMR assessment of MAPSE holds promise in refining risk assessment of AF in HCM patients. Combining structural and functional information in a simple ratio (LAVi/MAPSE) may represent a novel risk stratification tool with high predictive accuracy to detect patients with increased risk of AF (Figure C).

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are